{"doi":"10.29011/2833-3497.000157","title":"Metastatic Prostate Cancers at the University Hospital Center-Bogodogo (CHU-B) in OUAGADOUGOU : Situation in a Resource-Limited Country like Burkina Faso","abstract":"Abstract Prostate cancer is the leading cancer in men in Burkina Faso, contributing to an incidence rate of 26.3%, according to GLOBOCAN 2020. Metastatic prostate cancer (mPC) makes up about 30% of prostate cancer cases. Our objective was to examine the epidemiological, diagnostic, and treatment characteristics of mPC hospitalized and non-hospitalized instances within the Clinical Oncology and Hematology Department of the University Hospital Center-Bogodogo (CHU-B). This study adopted a descriptive cross-sectional approach, encompassing retrospective data acquisition from May 1, 2017, to April 30, 2020. All patients undergoing follow-up for mPC, with confirmed histological diagnosis and metastatic verification supported by clinical, radiological, and/or histological evidence, were included. Data was collected from individual records within patients’ clinical files. mPC comprised 76.6% of the diagnosed prostate cancer cases. The average age was 67.7 years [range: 50 to 89 years]. The typical interval before consultation was 29.7 months. Urinary symptoms were present in 87.7% of cases, while bone pain was reported in 75.5% of cases. Secondary bone involvement was identified in 78.26% of instances. The mean total PSA level was 1179.28 ng/ml, [range: 7 to 9976 ng/ml]. The complete androgen blockade protocol was utilized for treatment in 69.3% of patients, with the Docetaxel protocol being employed in 26.5% of cases. The median survival duration was 8.13 months. mPC was predominant among prostate cancers, underscoring the urgency of promptly implementing Burkina Faso’s strategic plan for cancer control.","journal":"Annals of Medical and Clinical Oncology","year":2023,"id":414806,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9558,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1197073,"name":"#","orcid":null,"position":1,"is_corresponding":false},{"id":1197074,"name":"Zerbo Assanatou","orcid":null,"position":2,"is_corresponding":false},{"id":1197075,"name":"Nikiema Marie","orcid":null,"position":3,"is_corresponding":false},{"id":1197076,"name":"Kaboré Fasnéwendé Aristide","orcid":null,"position":4,"is_corresponding":false},{"id":430465,"name":"Valerie Odero‐Marah","orcid":"0000-0001-7525-4652","position":5,"is_corresponding":false},{"id":1153401,"name":"Bambara Hierrhum Aboubacar","orcid":null,"position":0,"is_corresponding":true}],"reference_count":12,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T01:22:08.814145Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}